Phase II Clinical Trial of Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer
No previous treatment.
The 21 day cycle of treatment will be given for four courses before being reassessed by
MRI/CT for resectability of their liver metastases.
Those patients with stable disease or partial response, but are not yet resectable will
continue for a further four courses of treatment before reassessment.
Patients whose liver metastases have become resectable will proceed to surgery after a 6
week break from the last administration of Capecitabine (8 weeks from the last
administration of Bevacizumab).
A further four courses of treatment will be administered post-operatively to commence at
least 8 weeks after surgery and when the patient is well recovered and healed.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rates
Royal Marsden NHS Foundation Trust
United Kingdom: Medicines and Healthcare Products Regulatory Agency